{
    "info": {
        "nct_id": "NCT03011814",
        "official_title": "A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma",
        "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Registered into Revlimid REMS program\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1\n* Relapsed/refractory disease\n* Failed >= 2 prior systemic therapies *NOTE: For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin\n\nCUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY\n\n* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB\n\n  * Stage of disease according to TNMB classification\n  * Pathology report must be diagnostic or be consistent with MF/SS criteria\n  * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\n  * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used\n* Measurable disease per modified severity weighted assessment tool (mSWAT) and/or Sezary count\n* Baseline skin biopsy taken within 6 months available for central review submission\n\nPERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY\n\n* Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria\n* Measurable and/or evaluable disease per Lugano Classification\n* Absolute neutrophil count (ANC) >= 1000/mm^3\n\n  * Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Platelets >= 100,000/mm^3\n\n  * Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total serum bilirubin =< 2.2 mg/dL\n* Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =< 2 x ULN\n* Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula\n* If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin (PT) =< 1.5 x ULN\n\n  * If on anticoagulant therapy: PT must be within therapeutic range of intended used of anticoagulants\n* Female of childbearing potential: negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female of child bearing potential: willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study medication\n\n  * Childbearing potential defined as not being surgically sterilized or have not been free from menses for > 1 year\n* Male: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer vaccines\n* Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)\n* Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy\n* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy\n* Any skin-directed therapy within 14 days prior to initiating protocol therapy\n* Any radiation therapy within 21 days prior to initiating protocol therapy\n* Immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\n  * Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent\n* Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy\n* History of pneumonitis (non-infectious) that required steroids or current pneumonitis\n* Disease free of prior malignancies for >= 5 years with the exception of:\n\n  * Currently treated squamous cell and basal cell carcinoma of the skin\n  * Carcinoma in situ of the cervix, or\n  * Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision or\n  * Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or\n  * Any other malignancy that has/have been curatively treated with surgery and/or localized radiation\n* Allergic reaction/ hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab\n* Female only: pregnant or lactating\n* Prior stem cell transplantation\n* Acute infection requiring systemic treatment\n* Known history of human immunodeficiency virus (HIV) infection\n* Active hepatitis B or C infection\n* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy\n* Current peripheral neuropathy >= grade 2\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment\n* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment; the following are exceptions to this criterion:\n\n  * Vitiligo or alopecia;\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or\n  * Psoriasis not requiring systemic treatment\n* History of primary immunodeficiency\n* Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide\n* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc\n* In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Stage of disease according to TNMB classification",
            "criterions": [
                {
                    "exact_snippets": "Stage of disease according to TNMB classification",
                    "criterion": "stage of disease (TNMB classification)",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "TNMB"
                        }
                    ]
                }
            ]
        },
        {
            "line": "PERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY",
            "criterions": [
                {
                    "exact_snippets": "PERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY",
                    "criterion": "diagnosis of peripheral T-cell lymphoma (PTCL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Baseline skin biopsy taken within 6 months available for central review submission",
            "criterions": [
                {
                    "exact_snippets": "Baseline skin biopsy taken within 6 months",
                    "criterion": "baseline skin biopsy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "baseline"
                        }
                    ]
                },
                {
                    "exact_snippets": "available for central review submission",
                    "criterion": "skin biopsy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "intended_use",
                            "expected_value": "central review submission"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per modified severity weighted assessment tool (mSWAT) and/or Sezary count",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per modified severity weighted assessment tool (mSWAT)",
                    "criterion": "measurable disease (mSWAT)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_tool",
                            "expected_value": "modified severity weighted assessment tool (mSWAT)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Measurable disease per ... Sezary count",
                    "criterion": "measurable disease (Sezary count)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_tool",
                            "expected_value": "Sezary count"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable and/or evaluable disease per Lugano Classification",
            "criterions": [
                {
                    "exact_snippets": "Measurable ... disease per Lugano Classification",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "Lugano Classification"
                        }
                    ]
                },
                {
                    "exact_snippets": "evaluable disease per Lugano Classification",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "evaluability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "Lugano Classification"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement",
            "criterions": [
                {
                    "exact_snippets": "Growth factor is not permitted within 14 days of ANC assessment",
                    "criterion": "growth factor administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless cytopenia is secondary to disease involvement",
                    "criterion": "cytopenia etiology",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "secondary to disease involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria",
                    "criterion": "PTCL (Peripheral T-cell lymphoma) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "World Health Organization (WHO) 2008 criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failed >= 2 prior systemic therapies *NOTE: For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin",
            "criterions": [
                {
                    "exact_snippets": "Failed >= 2 prior systemic therapies",
                    "criterion": "prior systemic therapies",
                    "requirements": [
                        {
                            "requirement_type": "number failed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin",
                    "criterion": "prior systemic therapy for systemic ALCL",
                    "requirements": [
                        {
                            "requirement_type": "inclusion of brentuximab vedotin progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed/refractory disease",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement",
            "criterions": [
                {
                    "exact_snippets": "Platelet transfusions are not permitted within 14 days of platelet assessment",
                    "criterion": "platelet transfusions",
                    "requirements": [
                        {
                            "requirement_type": "timing before platelet assessment",
                            "expected_value": {
                                "operator": "<",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless cytopenia is secondary to disease involvement",
                    "criterion": "cytopenia secondary to disease involvement",
                    "requirements": [
                        {
                            "requirement_type": "exception to platelet transfusion restriction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "urine test is positive or cannot be confirmed as negative",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "positive",
                                "cannot be confirmed as negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "a serum pregnancy test will be required",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female of childbearing potential: negative urine or serum pregnancy test",
            "criterions": [
                {
                    "exact_snippets": "Female of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria",
            "criterions": [
                {
                    "exact_snippets": "meeting T4 plus B2 criteria",
                    "criterion": "disease stage (SS)",
                    "requirements": [
                        {
                            "requirement_type": "T4 criterion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "B2 criterion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features",
                    "criterion": "erythrodermic skin biopsy histopathology",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic histopathological features",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "suggestive histopathological features",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis may be based on either node biopsy or fulfillment of B2 criteria",
                    "criterion": "diagnosis basis",
                    "requirements": [
                        {
                            "requirement_type": "node biopsy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "B2 criterion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total serum bilirubin =< 2.2 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Total serum bilirubin =< 2.2 mg/dL",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathology report must be diagnostic or be consistent with MF/SS criteria",
            "criterions": [
                {
                    "exact_snippets": "Pathology report must be diagnostic",
                    "criterion": "pathology report",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be consistent with MF/SS criteria",
                    "criterion": "pathology report",
                    "requirements": [
                        {
                            "requirement_type": "consistency with MF/SS criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of the participant and/or legally authorized representative",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of the participant",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "participant"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented informed consent ... legally authorized representative",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "legally authorized representative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin (PT) =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "If not receiving anticoagulants",
                    "criterion": "anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "international normalized ratio (INR) ... =< 1.5 x ULN",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin (PT) ... =< 1.5 x ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "CUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY",
            "criterions": [
                {
                    "exact_snippets": "CUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "cutaneous T-cell lymphoma (CTCL)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used",
            "criterions": [
                {
                    "exact_snippets": "MF where the histological diagnosis by light microscopic examination is not confirmed",
                    "criterion": "histological diagnosis of MF by light microscopic examination",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used",
                    "criterion": "diagnostic criteria used for MF diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "guideline",
                            "expected_value": "International Society of Cutaneous Lymphomas (ISCL) recommended criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1",
            "criterions": [
                {
                    "exact_snippets": "Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1",
                    "criterion": "acute toxicities of all prior therapies (except alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female of child bearing potential: willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study medication",
            "criterions": [
                {
                    "exact_snippets": "Female of child bearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to use 2 methods of birth control",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be surgically sterile",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "abstain from heterosexual activity for the course of the study through 90 days after the last dose of study medication",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the course of the study through 90 days after the last dose of study medication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS)",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "mycosis fungoides",
                                "Sezary syndrome"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF",
                    "criterion": "disease stage (Phase 1)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2.2,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "folliculotropic MF",
                                "transformed MF"
                            ]
                        },
                        {
                            "requirement_type": "stage (subtype)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1.1,
                                        "unit": "stage"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2.1,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase 2: >= stage IB",
                    "criterion": "disease stage (Phase 2)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1.1,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If on anticoagulant therapy: PT must be within therapeutic range of intended used of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "If on anticoagulant therapy",
                    "criterion": "anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "PT must be within therapeutic range of intended used of anticoagulants",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within therapeutic range for intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 2 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 2 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Childbearing potential defined as not being surgically sterilized or have not been free from menses for > 1 year",
            "criterions": [
                {
                    "exact_snippets": "Childbearing potential defined as not being surgically sterilized",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been free from menses for > 1 year",
                    "criterion": "menses-free duration",
                    "requirements": [
                        {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Registered into Revlimid REMS program",
            "criterions": [
                {
                    "exact_snippets": "Registered into Revlimid REMS program",
                    "criterion": "Revlimid REMS program registration",
                    "requirements": [
                        {
                            "requirement_type": "registration_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method adequacy",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "dose of study therapy"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after the last dose of study therapy"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Vitiligo or alopecia;",
            "criterions": [
                {
                    "exact_snippets": "Vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion:",
            "criterions": [
                {
                    "exact_snippets": "Immunosuppressive medication within 14 days prior to the first dose of study treatment",
                    "criterion": "immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal failure requiring hemodialysis or peritoneal dialysis",
            "criterions": [
                {
                    "exact_snippets": "Renal failure requiring hemodialysis or peritoneal dialysis",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "hemodialysis",
                                "peritoneal dialysis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide",
            "criterions": [
                {
                    "exact_snippets": "Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "incidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on lenalidomide absorption",
                            "expected_value": "may significantly alter"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable cardiac disease as defined by one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Unstable cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently treated squamous cell and basal cell carcinoma of the skin",
            "criterions": [
                {
                    "exact_snippets": "Currently treated squamous cell ... carcinoma of the skin",
                    "criterion": "squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "currently treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Currently treated ... basal cell carcinoma of the skin",
                    "criterion": "basal cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "currently treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer vaccines",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy with immune checkpoint inhibitors",
                    "criterion": "immunotherapy with immune checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Immunotherapy with ... cell-based therapies",
                    "criterion": "immunotherapy with cell-based therapies",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Immunotherapy with ... cancer vaccines",
                    "criterion": "immunotherapy with cancer vaccines",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or",
            "criterions": [
                {
                    "exact_snippets": "Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system)",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "TNM stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that has/have been surgically cured",
                    "criterion": "prostate cancer surgical cure",
                    "requirements": [
                        {
                            "requirement_type": "surgical cure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease free of prior malignancies for >= 5 years with the exception of:",
            "criterions": [
                {
                    "exact_snippets": "Disease free of prior malignancies for >= 5 years",
                    "criterion": "prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current peripheral neuropathy >= grade 2",
            "criterions": [
                {
                    "exact_snippets": "Current peripheral neuropathy >= grade 2",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment; the following are exceptions to this criterion:",
            "criterions": [
                {
                    "exact_snippets": "Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment",
                    "criterion": "autoimmune or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "prior documented"
                            ]
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years prior to the start of treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of primary immunodeficiency",
            "criterions": [
                {
                    "exact_snippets": "History of primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allergic reaction/ hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab",
            "criterions": [
                {
                    "exact_snippets": "Allergic reaction/ hypersensitivity to thalidomide",
                    "criterion": "allergic reaction or hypersensitivity to thalidomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Allergic reaction/ hypersensitivity ... to the excipients contained in the formulation of durvalumab",
                    "criterion": "allergic reaction or hypersensitivity to excipients in durvalumab formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or",
            "criterions": [
                {
                    "exact_snippets": "Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability on hormone replacement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled atrial fibrillation or hypertension",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled atrial fibrillation",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female only: pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Female only",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days",
            "criterions": [
                {
                    "exact_snippets": "Intranasal, inhaled, topical or local steroid injections",
                    "criterion": "steroid administration route",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "intranasal",
                                "inhaled",
                                "topical",
                                "local injection"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "on stable dose for at least 28 days",
                    "criterion": "steroid dose stability",
                    "requirements": [
                        {
                            "requirement_type": "duration of stable dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any radiation therapy within 21 days prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Any radiation therapy within 21 days prior to initiating protocol therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to initiating protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior stem cell transplantation",
                    "criterion": "stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carcinoma in situ of the cervix, or",
            "criterions": [
                {
                    "exact_snippets": "Carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NYHA (New York Heart Association) heart failure class III-IV",
            "criterions": [
                {
                    "exact_snippets": "NYHA (New York Heart Association) heart failure class III-IV",
                    "criterion": "NYHA heart failure class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psoriasis not requiring systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Psoriasis not requiring systemic treatment",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "not requiring systemic treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures",
                    "criterion": "other condition contraindicating participation",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraindication to participation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "reason",
                            "expected_value": [
                                "safety concerns",
                                "compliance with clinical study procedures"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "infection/inflammation",
                    "criterion": "infection or inflammation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to swallow medication",
                    "criterion": "ability to swallow medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "social/psychological issues",
                    "criterion": "social or psychological issues",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other malignancy that has/have been curatively treated with surgery and/or localized radiation",
            "criterions": [
                {
                    "exact_snippets": "Any other malignancy that has/have been curatively treated with surgery and/or localized radiation",
                    "criterion": "other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "curative surgery",
                                "curative localized radiation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac events such as myocardial infarction (MI) within the past 6 months",
            "criterions": [
                {
                    "exact_snippets": "Cardiac events such as myocardial infarction (MI) within the past 6 months",
                    "criterion": "myocardial infarction (MI)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any skin-directed therapy within 14 days prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Any skin-directed therapy within 14 days prior to initiating protocol therapy",
                    "criterion": "skin-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of pneumonitis (non-infectious) that required steroids or current pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "History of pneumonitis (non-infectious) that required steroids",
                    "criterion": "history of non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "current pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy",
                    "criterion": "monoclonal antibody administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "prior to the first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Conditions requiring chronic steroid or immunosuppressive treatment",
                    "criterion": "chronic steroid or immunosuppressive treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy",
                    "criterion": "need for additional steroid or immunosuppressive treatments",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent",
            "criterions": [
                {
                    "exact_snippets": "Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent",
                    "criterion": "systemic corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision or",
            "criterions": [
                {
                    "exact_snippets": "Surgically removed melanoma in situ of the skin (stage 0)",
                    "criterion": "melanoma in situ of the skin (stage 0)",
                    "requirements": [
                        {
                            "requirement_type": "surgical removal",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histological confirmed free margins of excision",
                    "criterion": "margins of excision",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "free margins",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)",
            "criterions": [
                {
                    "exact_snippets": "Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)",
                    "criterion": "immunomodulatory drug (IMiD) use",
                    "requirements": [
                        {
                            "requirement_type": "use or exposure",
                            "expected_value": [
                                "Lenalidomide",
                                "thalidomide",
                                "other immunomodulatory drugs (IMiDs)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute infection requiring systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Acute infection requiring systemic treatment",
                    "criterion": "acute infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Active hepatitis B or C infection",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}